Repligen | RGEN - Bruttoergebnis Vom Umsatz

Aktienkurs
115.18
Täglich Wechseln
2.07 1.83%
Monatlich
-2.24%
Jährlich
-16.05%
Q2 Prognose
115.08




Bruttoergebnis Vom Umsatz Veränderung Datum
Agilent USD 946M 44M 2025-12
Align Technology USD 736.59M 53M 2026-03
Bio Techne USD 191.28M 3.16M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Bruker USD 449.2M 69.8M 2025-12
Charles River Laboratories USD 271.96M 39.43M 2025-12
Danaher USD 3.59B 375M 2026-03
Dentsply International USD 443M 2M 2025-12
General Electric Aerospace USD 4.24B 439M 2026-03
Henry Schein USD 1.06B 37M 2025-12
Illumina USD 759M 26M 2025-12
IQVIA Holdings USD 1.12B 32M 2025-12
Mettler Toledo International USD 675.44M 65.98M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
OraSure Technologies USD 11.34M 435K 2025-12
Pacific Biosciences Of California USD 15.74M 601K 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Repligen USD 103.83M 3.32M 2025-12
Revvity USD 421.66M 47.06M 2025-12
Standard Biotools USD 11.38M 1.9M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Waters USD 557.42M 97.44M 2025-12
West Pharmaceutical Services USD 296.4M 7.5M 2026-03